In The Pipeline
Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.
Our Pipeline at a Glance as of June 18, 2020
Compounds in Development
Disease Areas Being Studied
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.
In the Pipeline Download Pipeline
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Please click on product name to see the Full U.S. Prescribing Information for OPDIVO®, YERVOY®, POMALYST®, EMPLICITI®, IDHIFA®, ISTODAX®, ORENCIA®, NULOJIX®, ELIQUIS®, REVLIMID®, REBLOZYL®, including Boxed WARNINGS for ELIQUIS®, REVLIMID®, POMALYST® and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions and IDHIFA® regarding differentiation syndrome and INREBIC® regarding encephalopathy including Wernicke's.
✦ Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; Cabozantinib: Exelixis; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen; HSP47: Nitto Denko; CD3xPSCA, GEM333: GeMoaB Monoclonals GmbH; bb21217, ide-cel: bluebird bio; REBLOZYL: Acceleron Pharma, IDHIFA: Agios Pharmaceuticals, Inc.; AHR: Ikena Oncology; CD22 ADC: TriPhase Accelerator; TYK2 Inhibitor (Nimbus): Nimbus Therapeutics; Immune Tolerance: Anokion
^ Trial(s) exploring various combinations
# Partner-run study
◊ Product is marketed as IMNOVID® in the EU
+ Idecabtagene vicleucel
○ Orvacabtagene autoleucel, being developed by Juno Therapeutics Inc., A Bristol-Myers Squibb Company
* Lisocabtagene maraleucel
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
SCCHN = Squamous Cell Carcinoma of the Head & Neck
HMA = Hypomethylating Agent
TCE = T-Cell Engager
ADC = Antibody Drug Conjugate
ESA = Erythoropoiesis-Stimulating Agent